Myriad Genetics Q4 adjusted EPS beats estimates

Myriad Genetics

23/02/2026 21:21

Overview

Molecular diagnostic firm's Adjusted EPS for Q4 beat analyst expectations

Company reaffirmed financial guidance for full-year 2026

Outlook

Myriad Genetics reaffirms full-year 2026 revenue guidance of $860 mln to $880 mln

Result Drivers

TEST VOLUME GROWTH - Prolaris prostate cancer test volume grew 12%, Hereditary cancer testing grew 9%, and GeneSight grew 9% year-over-year, attributed to strengthened execution across the commercial team

HEADWINDS IMPACT - Revenue growth was affected by the discontinuation of GeneSight coverage by UnitedHealthcare and the divestiture of the European EndoPredict business

Company press release: ID:nGNX3TLhKp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
$0.04
-$0.01 (13 Analysts)
Q4 EPS
-$0.08
Q4 Net Income
-$7.90 mln
Q4 Gross Margin
70.00%
Q4 Adjusted Operating Expenses
$139 mln
Q4 Operating Expenses
$152.50 mln
Q4 Operating Income
-$5.70 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 7 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Myriad Genetics Inc is $7.00, about 63.2% above its February 20 closing price of $4.29

The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 93 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)